Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONVERT-2: Neoadjuvant CAPOX Plus Pucotenlimab With Selective Radiotherapy in Locally Advanced Rectal Cancer
NCT07528209Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2026
- Primary completion
- Apr 2032
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of pucotenlimab in rectal cancer, sponsored by Sun Yat-sen University. Started Apr 2026; status: recruiting.
02
Drugs
pucotenlimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07528209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07528209.